Immune cell landscape and immunotherapy of medulloblastoma

J Zhang, T Wang - Pediatric investigation, 2021 - mednexus.org
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Immune cell landscape and immunotherapy of medulloblastoma.

J Zhang, T Wang - Pediatric Investigation, 2021 - europepmc.org
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Immune cell landscape and immunotherapy of medulloblastoma

J Zhang, T Wang - Pediatric Investigation, 2021 - search.proquest.com
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Immune cell landscape and immunotherapy of medulloblastoma

J Zhang, T Wang - Pediatric investigation, 2021 - pubmed.ncbi.nlm.nih.gov
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Immune cell landscape and immunotherapy of medulloblastoma

J Zhang, T Wang - Pediatric Investigation, 2021 - Wiley Online Library
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

Immune cell landscape and immunotherapy of medulloblastoma.

J Zhang, T Wang - Pediatric Investigation, 2021 - go.gale.com
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …

[HTML][HTML] Immune cell landscape and immunotherapy of medulloblastoma

J Zhang, T Wang - Pediatric Investigation, 2021 - ncbi.nlm.nih.gov
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …